(R,S)-N-苄基哌啶-3-甲酰胺 | 94379-05-2

• 分子结构分类: 有机化合物 - 有机杂环化合物 - 哌啶类
• 中文名称: (R,S)-N-苄基哌啶-3-甲酰胺
• 中文别名: 1-苄基哌啶-3-羧酰胺
• 英文名称: 1-benzyl-piperidine-3-carboxamide
• 英文别名: 1-Benzylpiperidine-3-carboxamide
• CAS: 94379-05-2
• 化学式: C₁₃H₁₈N₂O
• mdl: MFCD01467541
• 分子量: 218.299
• InChiKey: QKDBCVUPRORMPD-UHFFFAOYSA-N

物化性质

• 熔点：
  122-123 °C(Solv: water (7732-18-5))
• 沸点：
  390.4±31.0 °C(Predicted)
• 密度：
  1.123±0.06 g/cm3(Predicted)

计算性质

• 辛醇/水分配系数(LogP)：
  1.1
• 重原子数：
  16
• 可旋转键数：
  3
• 环数：
  2.0
• sp3杂化的碳原子比例：
  0.461
• 拓扑面积：
  46.3
• 氢给体数：
  1
• 氢受体数：
  2

反应信息

• 作为反应物：
  描述：

  (R,S)-N-苄基哌啶-3-甲酰胺 在 三氯氧磷 作用下， 以 二氯甲烷 为溶剂， 生成 1-苄基-哌啶-3-甲腈
  参考文献：
  名称：

  [EN] SUBSTITUTED 3- AND 4- AMINOMETHYLPIPERIDINES FOR USE AS BETA-SECRETASE IN THE TREATMENT OF ALZHEIMER'S DISEASE
  [FR] 3- ET 4- AMINOMETHYLPIPERIDINES SUBSTITUEES UTILISEES COMME BETA-SECRETASE DANS LE TRAITEMENT DE LA MALADIE D'ALZHEIMER

  摘要：

  本发明涉及新型化合物，其为通式（I）的3-或4-氨基甲基哌啶的取代手性或非手性衍生物。本发明还涉及包括制备这些化合物的工艺、含有一种或多种通式（I）化合物的药物组合物以及特别是它们作为β-分泌酶抑制剂用于治疗阿尔茨海默病的相关方面。

  公开号：

  WO2004002483A1
• 作为产物：
  描述：

  3-哌啶甲酸乙酯 在 ammonium hydroxide 、 sodium carbonate 作用下， 以 二氯甲烷 、 水 为溶剂， 反应 3.0h， 生成 (R,S)-N-苄基哌啶-3-甲酰胺
  参考文献：
  名称：

  A convenient route to 1-benzyl 3-aminopyrrolidine and 3-aminopiperidine

  摘要：

  1-Benzyl 3-aminopyrrolidine 1 and 1-benzyl 3-aminopiperidine 2 were prepared rapidly mainly in aqueous conditions in 55 and 75%, yields, respectively, on a multi-gram scale starting from inexpensive and commercially available starting materials. The key step involved the Curtius rearrangement mediated by sodium nitrite and trifluoroacetic acid of the appropriate acylhydrazides. All the reactions (except LAH reductions) were performed in water. (C) 2001 Elsevier Science Ltd. All rights reserved.

  DOI：

  10.1016/s0040-4039(01)00985-6

文献信息

• [EN] SUBSTITUTED (PIPERIDIN-1-YL)ARYL ANALOGUES FOR MODULATING AVILACTIVITY<br/>[FR] ANALOGUES DE (PIPÉRIDIN-1-YL)ARYLE SUBSTITUÉS POUR LA MODULATION DE L'ACTIVITÉ DE L'AVIL
  申请人：UNIV VIRGINIA PATENT FOUNDATION

  公开号：WO2020223715A1

  公开（公告）日：2020-11-05

  In one aspect, the disclosure relates to compounds useful to regulate, limit, or inhibit the expression of AVIL (advillin), methods of making same, pharmaceutical compositions comprising same, and methods of treating disorders associated with AVIL dysregulation using same. In aspects, the disclosed compounds, compositions and methods are useful for treating disorders or diseases in which the regulation, limitation, or inhibition of the expression of AVIL can be clinically useful, such as, for example, the treatment of cancer. This abstract is intended as a scanning tool for purposes of searching in the particular art and is not intended to be limiting of the present disclosure.

  在一个方面，该披露涉及到有用于调节、限制或抑制AVIL（advillin）表达的化合物，制备方法，包含相同化合物的药物组合物，以及使用相同化合物治疗与AVIL失调相关的疾病的方法。在披露的方面，所述的化合物、组合物和方法可用于治疗调节、限制或抑制AVIL表达在临床上有用的疾病或疾病，例如癌症的治疗。本摘要旨在作为在特定领域进行搜索的扫描工具，并不意味着限制本披露。
• [EN] CHEMICAL COMPOUNDS<br/>[FR] COMPOSÉS CHIMIQUES
  申请人：GLAXOSMITHKLINE LLC

  公开号：WO2010059658A1

  公开（公告）日：2010-05-27

  The invention is directed to 6-(4-pyιϊmidinyl)-1 H-indazole derivatives. Specifically, the invention is directed to compounds according to Formula (I) wherein R1 - R4 are defined herein. The compounds of the invention are inhibitors of PDK1 and can be useful in the treatment of immune and metabolic diseases and disorders characterized by constitutively activated ACG kinases such as cancer and more specifically cancers of the breast, colon, and lung. Accordingly, the invention is further directed to pharmaceutical compositions comprising a compound of the invention. The invention is still further directed to methods of inhibiting PDK1 activity and treatment of disorders associated therewith using a compound of the invention or a pharmaceutical composition comprising a compound of the invention.

  这项发明涉及6-(4-吡咯嗪基)-1 H-吲唑衍生物。具体而言，该发明涉及符合式(I)的化合物，其中R1-R4在此处被定义。该发明的化合物是PDK1的抑制剂，可用于治疗由于恒定激活的ACG激酶所特征化的免疫和代谢性疾病和紊乱，如癌症，更具体地说是乳腺癌、结肠癌和肺癌。因此，该发明进一步涉及包括该发明化合物的药物组合物。该发明还进一步涉及使用该发明化合物或包括该发明化合物的药物组合物来抑制PDK1活性和治疗相关疾病的方法。
• METHOD FOR PRODUCING OPTICALLY ACTIVE 3-AMINOPIPERIDINE OR SALT THEREOF
  申请人：Mori Kohei

  公开号：US20100105917A1

  公开（公告）日：2010-04-29

  The present invention relates to a method for producing an optically active 3-aminopiperidine or salt thereof. In the method, a racemic nipecotamide is stereoselectively hydrolyzed to obtain an optically active nipecotamide and an optically active nipecotic acid in the presence of an enzyme source derived from an organism, and then the optically active nipecotamide is derived into an optically active aminopiperidine or salt thereof by aroylation, Hofmann rearrangement, deprotection of the amino group and further deprotection; or the optically active nipecotamide is derived into an optically active aminopiperidine or salt thereof by selective protection with BOC, Hofmann rearrangement and further deprotection. It is possible by the present invention to produce an optically active 3-aminopiperidine or salt thereof useful as a pharmaceutical intermediate from an inexpensive and easily available starting material by easy method applicable to industrial manufacturing.

  本发明涉及一种生产光学活性3-氨基哌啶或其盐的方法。在该方法中，通过在有机体衍生的酶源存在下，立体选择性水解一个混合的尼皮科酰胺来获得光学活性尼皮科酰胺和光学活性尼皮科酸，然后通过酰化、霍夫曼重排、氨基保护基的去除和进一步的去保护，将光学活性尼皮科酰胺转化为光学活性氨基哌啶或其盐；或者通过用BOC进行选择性保护、霍夫曼重排和进一步的去保护，将光学活性尼皮科酰胺转化为光学活性氨基哌啶或其盐。通过本发明，可以从廉价且易得的起始材料中通过简单的工业制造方法生产出一种作为药物中间体有用的光学活性3-氨基哌啶或其盐。
• Better than Nature: Nicotinamide Biomimetics That Outperform Natural Coenzymes
  作者：Tanja Knaus、Caroline E. Paul、Colin W. Levy、Simon de Vries、Francesco G. Mutti、Frank Hollmann、Nigel S. Scrutton

  DOI：10.1021/jacs.5b12252

  日期：2016.1.27

  on unstable and expensive nicotinamide coenzymes that have prevented their widespread exploitation. Stoichiometric use of natural coenzymes is not viable economically, and the instability of these molecules hinders catalytic processes that employ coenzyme recycling. Here, we investigate the efficiency of man-made synthetic biomimetics of the natural coenzymes NAD(P)H in redox biocatalysis. Extensive

  寻找经济实惠的绿色生物催化工艺是化学品制造面临的挑战。氧化还原生物转化具有潜在的吸引力，但它们依赖于不稳定且昂贵的烟酰胺辅酶，这阻碍了它们的广泛利用。天然辅酶的化学计量使用在经济上是不可行的，并且这些分子的不稳定性阻碍了使用辅酶回收的催化过程。在这里，我们研究了天然辅酶 NAD(P)H 的人造合成仿生物在氧化还原生物催化中的效率。对属于“烯”还原酶家族的一系列氧化还原酶的广泛研究表明，这些仿生物是天然辅酶的极好类似物，在具有选定仿生物的烯还原酶 XenA 的晶体结构中也有所揭示。在选定的情况下，这些仿生学优于天然辅酶。“Better-than-Nature”仿生学应该通过利用高立体选择性、区域选择性和化学选择性氧化还原生物催化剂的力量并在温和条件下以低成本实现反应而在精细和特种化学品生产中得到广泛应用。
• Method for producing optically active 3-aminopiperidine or salt thereof
  申请人：Kaneka Corporation

  公开号：US08338142B2

  公开（公告）日：2012-12-25

  The present invention relates to a method for producing an optically active 3-aminopiperidine or salt thereof. In the method, a racemic nipecotamide is stereoselectively hydrolyzed to obtain an optically active nipecotamide and an optically active nipecotic acid in the presence of an enzyme source derived from an organism, and then the optically active nipecotamide is derived into an optically active aminopiperidine or salt thereof by aroylation, Hofmann rearrangement, deprotection of the amino group and further deprotection; or the optically active nipecotamide is derived into an optically active aminopiperidine or salt thereof by selective protection with BOC, Hofmann rearrangement and further deprotection. It is possible by the present invention to produce an optically active 3-aminopiperidine or salt thereof useful as a pharmaceutical intermediate from an inexpensive and easily available starting material by easy method applicable to industrial manufacturing.

  本发明涉及一种制备光学活性3-氨基哌啶或其盐的方法。在该方法中，利用来源于生物体的酶源，在立体选择性水解中得到光学活性的尼佩考胺和光学活性的尼佩考酸，然后通过酰化、霍夫曼重排、氨基保护基的去除和进一步去保护，或者通过选择性BOC保护、霍夫曼重排和进一步去保护将光学活性的尼佩考胺转化为光学活性的氨基哌啶或其盐。本发明可以通过简单的工业制造方法，从廉价易得的起始材料中制备出用于制药中间体的光学活性3-氨基哌啶或其盐。